Hyperendemic clone of KPC producing Klebsiella pneumoniae ST 258 in Buenos Aires hospitals

Cejas, Daniela; Canigia, Liliana Fernández; Nastro, Marcela; Rodriguez, Cynthia; Tanco, Ana; Rodríguez, Hernán B.; Vay, Carlos; Maldonado, Ivana; Famiglietti, Ángela; Giovanakis, Marta; Magariños, Francisco; Berardinelli, Elena M.; Neira, Liliana Isabel; Mollerach, Marta; Gutkind, Gabriel; Radice, Marcela

doi:10.1016/j.meegid.2011.09.018

Cited by 17 publications

(7 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Even if previous studies performed in Argentina showed that KPC-K. pneumoniae dissemination corresponded to the propagation of a unique clone, ST258 [6,7], today CC258 accounted for only 37% of the isolates (ST258 (26 %), ST11 (11%)). New lineages of KPC-K. pneumoniae were detected, and among them, a high proportion of isolates (42%) belonged to the emerging ST25, a virulent and hypermucoviscous clone which presents the capsular serotype K2.…”

Section: Discussionmentioning

confidence: 84%

See 1 more Smart Citation

Changing epidemiology of KPC-producing Klebsiella pneumoniae in Argentina: Emergence of hypermucoviscous ST25 and high-risk clone ST307

Cejas

Elena

Nuñez

et al. 2019

Journal of Global Antimicrobial Resistance

Self Cite

View full text Add to dashboard Cite

Objectives: To assess the epidemiological features of 76 KPC producing K. pneumoniae isolates (KPC-Kp) recovered in 3 hospitals of Buenos Aires, Argentina, during 2015-2017. Methods: Antimicrobial susceptibilities were determined according to CLSI. Molecular typing of KPC-Kp was performed by PFGE-XbaI and MLST. Plasmid encoded genes involved in carbapenem, fosfomycin and colistin resistance were detected by PCR and sequencing. Also mgrB inactivation was investigated in those colistin resistance isolates. Genetic platforms involved in horizontal spread of bla KPC were investigated by PCR mapping.Results: Besides β-lactams, high resistance rates were observed for gentamycin, quinolones and trimethoprim-sulfamethoxazole. KPC-Kp ST258 corresponded to

show abstract

Section: Discussionmentioning

confidence: 84%

“…A N U S C R I P T between ST11 and ST442 [3][4][5]. This clone emerged in Argentina in 2010 becoming the prevalent ST and achieving epidemic status in many settings [6,7]. CC258 includes multidrug resistant microorganisms, displaying resistance to all β-lactams, aminoglycosides, quinolones, trimethoprim and sulfonamides [2].…”

Section: A C C E P T E D Mmentioning

confidence: 99%

Changing epidemiology of KPC-producing Klebsiella pneumoniae in Argentina: Emergence of hypermucoviscous ST25 and high-risk clone ST307

Cejas

Elena

Nuñez

et al. 2019

Journal of Global Antimicrobial Resistance

Self Cite

View full text Add to dashboard Cite

show abstract

“…The successful dissemination of K. pneumoniae isolates belonging to clonal complex 258 was a critical factor resulting in their pandemic expansion (6). In our country, a substantial increase of KPC-2-producing K. pneumoniae was observed in 2010, due to the huge dissemination of the hyperendemic sequence type 258 (ST258) clone, which displayed a multidrug-resistant phenotype (5,7,8). A multilocus sequence typing (MLST) scheme was conducted on K. pneumoniae 3089 (9).…”

mentioning

confidence: 99%

First Isolate of KPC-2-Producing Klebsiella pneumonaie Sequence Type 23 from the Americas

et al. 2014

Self Cite

View full text Add to dashboard Cite

KPC-2-producing Klebsiella pneumoniae isolates mainly correspond to clonal complex 258 (CC258); however, we describe KPC-2-producing K. pneumoniae isolates belonging to invasive sequence type 23 (ST23). KPC-2 has scarcely been reported to occur in ST23, and this report describes the first isolation of this pathogen in the Americas. Acquisition of resistant markers in virulent clones could mark an evolutionary step toward the establishment of these clones as major nosocomial pathogens.

show abstract

“…The alarming emergence of this pathogen is due to the wide dissemination of different variants with the increasing ability to resist several antibiotic treatments, including carbapenems. In fact, carbapenemase-producing K. pneumoniae strains have been associated with a wide range of hospital acquired-infections and are associated with high morbidity and mortality rates [ 1 , 2 , 3 ]. In recent years, an increase in the prevalence of hypermucoviscous carbapenem-resistant K. pneumoniae of the sequence type (ST) 25 was detected in patients hospitalized in Northwest Argentina.…”

Section: Introductionmentioning

confidence: 99%

Oral Administration of Lacticaseibacillus rhamnosus CRL1505 Modulates Lung Innate Immune Response against Klebsiella pneumoniae ST25

et al. 2023

View full text Add to dashboard Cite

Orally administered Lacticaseibacillus rhamnosus CRL1505 enhances respiratory immunity, providing protection against respiratory viruses and Streptococcus pneumoniae. However, the capacity of the CRL1505 strain to improve respiratory immunity against Gram-negative bacterial infections has not been evaluated before. The aim of this work was to evaluate whether the Lcb. rhamnosus CRL1505 was able to beneficially regulate the respiratory innate immune response and enhance the resistance to hypermucoviscous KPC-2-producing Klebsiella pneumoniae of the sequence type 25 (ST25). BALB/c mice were treated with the CRL1505 strain via the oral route and then nasally challenged with K. pneumoniae ST25 strains LABACER 01 or LABACER 27. Bacterial cell counts, lung injuries and the respiratory and systemic innate immune responses were evaluated after the bacterial infection. The results showed that K. pneumoniae ST25 strains increased the levels of TNF-α, IL-1β, IL-6, IFN-γ, IL-17, KC and MPC-1 in the respiratory tract and blood, as well as the numbers of BAL neutrophils and macrophages. Mice treated with Lcb. rhamnosus CRL1505 had significantly lower K. pneumoniae counts in their lungs, as well as reduced levels of inflammatory cells, cytokines and chemokines in the respiratory tract and blood when compared to infected controls. Furthermore, higher levels of the regulatory cytokines IL-10 and IL-27 were found in the respiratory tract and blood of CRL1505-treated mice than controls. These results suggest that the ability of Lcb. rhamnosus CRL1505 to help with the control of detrimental inflammation in lungs during K. pneumoniae infection would be a key feature to improve the resistance to this pathogen. Although further mechanistic studies are necessary, Lcb. rhamnosus CRL1505 can be proposed as a candidate to improve patients’ protection against hypermucoviscous KPC-2-producing strains belonging to the ST25, which is endemic in the hospitals of our region.

show abstract

Hyperendemic clone of KPC producing Klebsiella pneumoniae ST 258 in Buenos Aires hospitals

Cited by 17 publications

References 12 publications

Changing epidemiology of KPC-producing Klebsiella pneumoniae in Argentina: Emergence of hypermucoviscous ST25 and high-risk clone ST307

Changing epidemiology of KPC-producing Klebsiella pneumoniae in Argentina: Emergence of hypermucoviscous ST25 and high-risk clone ST307

First Isolate of KPC-2-Producing Klebsiella pneumonaie Sequence Type 23 from the Americas

Oral Administration of Lacticaseibacillus rhamnosus CRL1505 Modulates Lung Innate Immune Response against Klebsiella pneumoniae ST25

Contact Info

Product

Resources

About